Inventiva, with headquarters in Daix, France, received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the company’s lanifibranor for nonalcoholic steatohepatitis (NASH).

Waltham, Massachusetts-based biotech firm Skyhawk Therapeutics is expanding a strategic collaboration deal with Merck as the two companies are working to develop and commercialize a particular type of therapy built on modulating RNA splicing using Skyhawk’s SkySTAR technology platform.

Researchers at the University of Pennsylvania and Children’s National Hospital in Washington, D.C., utilized a hybrid approach that combined gene therapy with gene editing to treat a rare genetic disease in animal models.

Copenhagen-based Zealand Pharma announced a bid to buy substantially all the assets from New Jersey-based Valeritas in $23 million in cash and taking on certain liabilities.

With $28.5 million in financing, Cambridge, Mass.-based Comet Therapeutics is emerging from stealth mode with a focus on developing a portfolio of drug candidates that centers around efforts to re-engineer CoEnzyme-A (CoA).

TARGET PharmaSolutions Inc. – a real-world clinical data company – and Boehringer Ingelheim International GmbH entered into a multi-year strategic partnership for TARGET-NASH, a longitudinal observational study that evaluates patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).

AstraZeneca agreed to sell the U.S. rights to a portfolio of anesthetics to South Africa’s Aspen Group.

(Reuters Health) – People who get less than six hours of sleep a night may be more likely to have risk factors that increase their odds of diabetes, heart disease and strokes, a Korean study suggests. This combination of risk factors – including high blood sugar, high cholesterol, extra fat around the midsection, high blood […]

Novo Nordisk (NVO), headquartered in Copenhagen, Denmark, announced yesterday that it will buy Calibrium LLC and MB2 LLC, two private biopharma companies based in Indiana.   Calibrium, located in Carmel, Ind., focuses on developing drug candidates for diabetes and related metabolic diseases. It was co-founded by Fritz French, the company’s chief executive officer, and Richard […]